PREVIEW: Hims & Hers dips; focus on weigth-loss drug

Hims & Hers Health HIMS shares declining 1.2% on Mon ahead of qtrly results after the bell, as investors watch for signs of subscriber recovery and weight-loss drug sales momentum

Analysts expect qtrly rev up 44% to $580.2 mln, adj EPS seen at $0.10 vs $0.32 yr-ago, per LSEG; report key after last qtr missed rev ests and saw subscriber losses

Prev qtrly report on August 4 showed a decline in subscribers in sexual health business, while a move from branded to lower-cost weight loss treatments led to lower revenue per subscriber

HIMS is shifting to creating copies of Novo Nordisk's NOVOb.CO Wegovy weight-loss drug in smaller 'personalized' doses after the U.S. Food and Drug Administration sunset the mass compounding it had allowed. NOVO has characterized mass personalization as illegal

HIMS stock has rallied about 86% YTD, far outpacing S&P 500 .SPX up 16%

Stock recently at 60x expected earnings, below 5-yr avg forward PE of 74